Growth Metrics

Pacific Biosciences Of California (PACB) Change in Receivables (2016 - 2025)

Pacific Biosciences Of California has reported Change in Receivables over the past 16 years, most recently at $4.8 million for Q4 2025.

  • Quarterly results put Change in Receivables at $4.8 million for Q4 2025, up 359.92% from a year ago — trailing twelve months through Dec 2025 was $7.9 million (up 187.16% YoY), and the annual figure for FY2025 was $7.9 million, up 187.16%.
  • Change in Receivables for Q4 2025 was $4.8 million at Pacific Biosciences Of California, up from -$1.6 million in the prior quarter.
  • Over the last five years, Change in Receivables for PACB hit a ceiling of $10.8 million in Q1 2023 and a floor of -$6.3 million in Q1 2024.
  • Median Change in Receivables over the past 5 years was $295000.0 (2021), compared with a mean of $768473.7.
  • Biggest five-year swings in Change in Receivables: tumbled 1445.76% in 2022 and later skyrocketed 359.92% in 2025.
  • Pacific Biosciences Of California's Change in Receivables stood at $295000.0 in 2021, then tumbled by 1445.76% to -$4.0 million in 2022, then soared by 254.38% to $6.1 million in 2023, then crashed by 130.33% to -$1.9 million in 2024, then surged by 359.92% to $4.8 million in 2025.
  • The last three reported values for Change in Receivables were $4.8 million (Q4 2025), -$1.6 million (Q3 2025), and $612000.0 (Q2 2025) per Business Quant data.